Search jobs 10-Mar-2021 Pyrogen Testing Market 2021 With Top Countries Data : Industry Trends, Growth, Size, Segmentation, Affect On Demand By COVID-19 Pandemic Demand, Latest Innovation, Sales Revenue by Regional Forecast to 2027 |
Pune, Maharashtra, India, March 10 2021 (Wiredrelease) Brandessence Market Research and Consulting Pvt ltd –:Pyrogen Testing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Increasing pharmaceutical & biotechnology companies and increasing investments in research & development are key drivers for Global Pyrogen Testing Market.
Scope of Global Pyrogen Testing Market Reports –
A pyrogen is a foreign substance that evokes temperature elevation in an animal’s body. Typically, pyrogenic substances include endotoxin and other bacterial by products. Pyrogen detection is mandatory in pharmaceutical, biotechnology or medical devices industries in order to avoid the fev
Hutchison China MediTech Limited Reports 2020 Full Year Results and Provides Business Updates
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U S FDA for the Treatment of Nasopharyngeal Carcinoma
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
(1)
- BLA submitted with FDA s breakthrough therapy designation -
SHANGHAI, China and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd. ( Junshi Biosciences , HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. ( Coherus , Nasdaq: CHRS) announced today the initiation of the rolling submission of the Biologics License Application ( BLA ) for toripalimab to the U.S. Food and Drug Administration ( FDA ) for the treatment of recurrent or metastatic nasopharyngeal carcinoma ( NPC ). A rolling submission allows Junshi Biosciences to submit sections of the BLA to the FDA as they are completed.
Toripalimab has been granted Breakthrough Therapy Designation by the FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma based on preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing therapies. The designation is intended to expedite the development and review of drugs for
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, Feb. 28, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent ) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient outside China has been successfully dosed in a Phase 1 clinical trial of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody (IBI322).
This is a Phase 1a clinical study conducted in the United States to evaluate IBI322 in the treatment of patients with advanced malignancies. The primary objective of the study is to evaluate the safety, tolerability, and initial anti-tumor efficacy of IBI322 in patients with advanced malignancies who have failed standard therapy.